Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514733 | 0.72 | GRM3 (0.53) | GRM3FOLH1 | |
| SCHEMBL27615261 | 0.71 | SMN1; SMN2 (0.42) | FOLH1 | |
| SCHEMBL28685286 | 0.69 | LTA4H (0.56) | — | |
| SCHEMBL21690121 | 0.69 | LTA4H (0.56) | — | |
| SCHEMBL14947069 | 0.69 | CYP1A2 (0.43) | — | |
| SCHEMBL7850584 | 0.69 | LTA4H (0.56) | — | |
| Water SCHEMBL29398886 | 0.68 | LTA4H (0.55) | — | |
| Water SCHEMBL29401417 | 0.68 | LTA4H (0.55) | — | |
| SCHEMBL3516033 | 0.68 | ALDH1A1 (0.38) | — | |
| SCHEMBL29412205 | 0.68 | CASP1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110318290-A1 | Compounds and Methods for Inhibiting Axillary Malodour | GIVAUDAN SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20100278768-A1 | Compounds and Methods for Inhibiting Axillary Malodour | GIVAUDAN SA (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7264956-B2 | N-alpha-acyl-glutamine-aminoacylase for identifying enzyme inhibitors which prevent/supress sweating odor; deodorants | GIVAUDAN SA (CH) | 2007-09-04 | — | — | US | disclosed |
| EP-1811034-A2 | Compounds and method for inhibiting axillary malodour | Givaudan SA (CH) | 2007-07-25 | — | — | EP | disclosed |
| US-20040241795-A1 | Compounds and methods for inhibiting axillary malodour | GIVAUDAN SA (CH) | 2004-12-02 | — | — | US | disclosed |
| EP-1387891-A2 | COMPOUNDS AND METHODS FOR INHIBITING AXILLARY MALODOUR | Givaudan SA (CH) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092024-A2 | COMPOUNDS AND METHODS FOR INHIBITING AXILLARY MALODOUR | GIVAUDAN SA (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318290-A1 | Compounds and Methods for Inhibiting Axillary Malodour | TYR, AOX1, APEH | GRM3 4378/4885FOLH1 464/4885 |
| US-20100278768-A1 | Compounds and Methods for Inhibiting Axillary Malodour | TYR, AOX1, APEH | GRM3 4378/4885FOLH1 464/4885 |
| US-20040241795-A1 | Compounds and methods for inhibiting axillary malodour | AOX1, TYR, ME1 | GRM3 4209/4885FOLH1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.